Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, Randomized, Parallel group study for Pharmacokinetics and Safety of Etrasimod following Single and Multiple Oral Dosing in Japanese and Caucasian Healthy Male Subject

Next Previous
Trial Profile

A prospective, Randomized, Parallel group study for Pharmacokinetics and Safety of Etrasimod following Single and Multiple Oral Dosing in Japanese and Caucasian Healthy Male Subject

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etrasimod (Primary)
  • Indications Alopecia areata; Atopic dermatitis; Autoimmune disorders; Crohn's disease; Eosinophilic oesophagitis; Ulcerative colitis
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 23 May 2021 Results (n=49) evaluating the effect of etrasimod on circulating lymphocyte subsets in healthy volunteers to improve understanding of its proposed mechanism of action (MOA). presented at the Digestive Disease Week 2021
  • 07 May 2020 New trial record
  • 21 Mar 2020 Results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top